A Registry Study of Shuxuening Injection Used in Hospitals in China (RSCMI-VII)
|ClinicalTrials.gov Identifier: NCT01752946|
Recruitment Status : Unknown
Verified December 2012 by Xie Yanming, China Academy of Chinese Medical Sciences.
Recruitment status was: Active, not recruiting
First Posted : December 19, 2012
Last Update Posted : December 20, 2012
|Condition or disease|
|Coronary Disease Intracranial Embolism Stroke Angina Pectoris Vasospasm|
Ginkgo leaf is major component of Shuxuening injection. Although some western countries product similar injections and use them, Shuxuening injection also regarded as Chinese medicine injection. As a TCM injection, the most important thing is how to safety use it in practice.
In order to improving monitoring adverse events or adverse drug reaction of Chinese medicine injection in hospital, registry study is suitable method in this area. Otherwise, nested case control study is used to find out the mechanism of allergic reaction.
Calculate the incidence of adverse events or adverse drug reaction is one of the main aims for this study. Safety surveillance on Chinese Medicine injection is an important problem that needs to be sorted out through large sample observational study.
According to the 'rule of three', 30,000 cases need to be registered at least. The aim population is who using Shuxuening injection's during inpatient time from December 2012 to December 2014.
Data will be collected for three departments as following:
Form A (green): demographic information ；Form B (pink): adverse drug events/reaction； Form C (white): extracted information from hospital information system and laboratory information system.
|Study Type :||Observational|
|Estimated Enrollment :||30000 participants|
|Official Title:||A Registry Study of Shuxuening (a Chinese Medicine Injection) Used in Hospitals in China|
|Study Start Date :||October 2012|
|Estimated Primary Completion Date :||December 2015|
|Estimated Study Completion Date :||December 2015|
- Incidence of Shuxuening injection's ADRs and factors contributed to the occurrence of the adverse reaction [ Time Frame: to assess Shuxuening's "adverse event" and "drug adverse reaction" during patients' hospital stay, administration information of Shuxuening will be registered every day. The registry procedure will last 2 years only for patients using Shuxuening. ]All participants will be followed for the duration of hospital stay, an expected average of 2 weeks. Patients using Shuxuening will be registered on a registration form including disease background, Shuxuening's administration, and extraction information from hospital information system. When the patients occurs allergic reaction during using Shuxuening injection, it also need to collect patient's biological samples. An adverse event or drug adverse reaction form also will be used to describe any doubted symptoms or signs from patients. A judgment will be made by doctors directly and a further analysis will be conducted by researchers to decide those potential side-effects of Shuxuening injection.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01752946
|Principal Investigator:||Yan M Xie, BA||Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences|